Multiple sclerosis is a chronic disease in which the immune system attacks the protective myelin sheath wrapped around nerve fibers. The result is a slow accumulation of neurological damage that researchers have spent decades trying to interrupt. Most approved therapies focus on dampening immune activity, but scientists have increasingly wondered whether peptides that work through metabolic pathways might also play a role.
A class of peptides called glucagon-like peptide-1 receptor agonists, or GLP-1 receptor agonists, has attracted particular attention. These compounds mimic a naturally occurring gut hormone and activate a receptor found not only in the pancreas but also throughout the brain and immune system. A 2026 systematic review published in Multiple Sclerosis and Related Disorders set out to collect and evaluate all available preclinical and clinical evidence on what happens when GLP-1 receptor agonists are studied in the context of MS.
The review was registered on PROSPERO and followed PRISMA 2020 reporting guidelines, making it the first formally registered synthesis of this evidence base. Fifteen studies cleared the authors' inclusion criteria, spanning animal models, human observational data, and pharmacovigilance databases. The picture that emerged is one of genuine scientific interest alongside an honest acknowledgment that rigorous human trials have not yet been done.
How the review was structured
The researchers searched PubMed, Scopus, and Google Scholar through June 2026, looking for any study that examined GLP-1 receptor agonists in confirmed MS patients, in experimental autoimmune encephalomyelitis (EAE) animal models, or in case reports. EAE is the most widely used laboratory model of MS, in which animals develop immune-driven demyelination that resembles key features of the human disease.
Fifteen studies met the inclusion bar. Eight were preclinical animal experiments, six using the EAE model and two using a different model called the cuprizone model. Four were human observational studies, and three were classified as narrative-context studies. Risk of bias was evaluated using the SYRCLE tool for animal work and the Newcastle-Ottawa Scale for human studies. The authors were transparent that most preclinical studies carried high risk of bias, while human studies were rated moderate to high risk of bias.
Preclinical findings in animal models
Across the eight animal studies, GLP-1 receptor agonists consistently reduced clinical severity scores in EAE models. The mechanisms reported were varied, which the authors treated as a sign that the effect may involve several biological pathways rather than a single narrow action.
One repeatedly observed pathway involved activation of AMPK and SIRT1, two proteins associated with cellular energy regulation and stress responses. Another involved suppression of the NLRP3 inflammasome, a molecular complex that drives inflammatory signaling in immune cells. Researchers also documented modulation of Th1 and Th17 immune cell populations, which are considered important contributors to MS pathology, as well as deactivation of microglia, the brain's resident immune cells.
Together, these findings suggest that GLP-1 receptor activation touches several nodes of the inflammatory and neuroprotective machinery relevant to demyelinating disease. That said, the authors noted that the high risk of bias in preclinical work means these findings should be interpreted cautiously. Animal models of MS do not perfectly replicate the human disease, and many compounds that look promising in EAE have not translated into clinical benefit.
What human data currently exists
The human evidence base is thin and observational. Two cohort studies together included 109 people with MS who were using GLP-1 receptor agonists, primarily for metabolic reasons. In these cohorts, researchers observed reductions in body mass index and increases in vitamin D levels. Neither cohort showed a change in the Expanded Disability Status Scale score, which is the standard measure of neurological disability in MS, nor did relapse rates shift.
The authors interpreted the absence of worsening as reassuring rather than evidence of benefit. In other words, using these peptides for metabolic purposes did not appear to harm neurological status in this small, uncontrolled group. Whether that observation would hold across larger and more diverse populations, or whether any neurological benefit would emerge with longer follow-up, cannot be determined from observational data alone.
A survey conducted through the NARCOMS patient registry, which included 4,181 respondents, found that 7.4 percent reported ever having used a GLP-1 receptor agonist. That figure gives researchers a sense of how common incidental use already is among people living with MS, which could inform the feasibility of future trials.
Pharmacovigilance signals
The review also examined pharmacovigilance data, which tracks adverse event reports submitted to regulatory databases. Researchers calculated reporting odds ratios for MS-related adverse events in people using GLP-1 receptor agonists compared to other drugs in the database.
The results showed inverse reporting odds ratios for three peptides in this class. An inverse ratio below 1.0 means that MS-related events were reported less often in association with these compounds than would be expected by chance in the broader database. The values observed were 0.238, 0.165, and 0.161 for three different GLP-1 receptor agonists. While pharmacovigilance cannot establish causation and is subject to well-known biases including underreporting and channeling effects, the authors considered these signals consistent with the preclinical picture rather than contradictory to it.
Separately, a Mendelian randomization analysis, a genetic technique used to test causal hypotheses, found no causal association between GLP-1 receptor activation and susceptibility to developing MS in the first place. This suggests that even if the peptides have effects after MS is established, they are unlikely to alter who gets the disease.
The mechanistic case for further research
One reason the preclinical findings are taken seriously by researchers is that the GLP-1 receptor is not confined to tissues involved in blood sugar regulation. It is expressed in the central nervous system, including in neurons and microglia. This biological distribution means there is a plausible anatomical basis for investigating whether GLP-1 signaling influences neuroinflammation directly, rather than only through systemic metabolic changes.
The AMPK and SIRT1 pathways highlighted in animal studies are associated with mitochondrial function and cellular resilience. Mitochondrial dysfunction has been documented in MS lesions and may contribute to neuronal loss independent of demyelination. The NLRP3 inflammasome, another target observed in these studies, has been linked to inflammatory cascades in several neurological conditions. None of this constitutes proof of efficacy in humans, but it does give researchers a mechanistic framework to design and interpret future trials.
The review's authors described these overlapping mechanisms as a feature rather than a noise, arguing that a compound affecting multiple relevant targets could in theory be more durable than one with a single narrow action. That hypothesis, however, remains untested in MS.
What the review concludes and what comes next
The authors' bottom line is straightforward. Preclinical evidence is consistent and mechanistically plausible, human evidence shows metabolic benefit without apparent neurological harm, and pharmacovigilance data does not raise safety concerns. What does not yet exist is a randomized controlled trial in MS patients designed to measure neurological outcomes.
The review calls such trials urgently needed, and the existing observational evidence suggests they are feasible. People with MS are already using these peptides for metabolic reasons at a measurable rate, vitamin D and metabolic outcomes appear to improve, and no signal of neurological worsening has been detected in the available data.
For readers following the research literature on peptides and neurology, this systematic review provides a useful map of where the evidence stands and, just as importantly, where it does not yet go. The honest finding is that compelling preclinical biology and cautiously encouraging safety signals together justify the next step in research, which is a properly designed clinical trial.
